Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
17.50
-0.20 (-1.13%)
At close: Aug 29, 2025, 4:00 PM
17.49
-0.01 (-0.06%)
After-hours: Aug 29, 2025, 6:21 PM EDT
Travere Therapeutics Revenue
Travere Therapeutics had revenue of $114.45M in the quarter ending June 30, 2025, with 111.49% growth. This brings the company's revenue in the last twelve months to $333.87M, up 87.94% year-over-year. In the year 2024, Travere Therapeutics had annual revenue of $233.18M with 60.55% growth.
Revenue (ttm)
$333.87M
Revenue Growth
+87.94%
P/S Ratio
4.43
Revenue / Employee
$867,182
Employees
385
Market Cap
1.56B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 233.18M | 87.94M | 60.55% |
Dec 31, 2023 | 145.24M | 35.78M | 32.69% |
Dec 31, 2022 | 109.46M | -22.38M | -16.97% |
Dec 31, 2021 | 131.84M | -66.49M | -33.52% |
Dec 31, 2020 | 198.32M | 22.98M | 13.11% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
TVTX News
- 3 days ago - FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari - Benzinga
- 4 days ago - Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI® (sparsentan) in IgA Nephropathy - Business Wire
- 19 days ago - Travere Therapeutics: Compelling FILSPARI Growth Is Hard To Ignore - Seeking Alpha
- 20 days ago - Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 24 days ago - Travere Therapeutics, Inc. (TVTX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 25 days ago - Travere Therapeutics Reports Second Quarter 2025 Financial Results - Business Wire
- 26 days ago - Travere Therapeutics to Participate at Upcoming Investor Conferences - Business Wire
- 4 weeks ago - Travere Therapeutics to Report Second Quarter 2025 Financial Results - Business Wire